[{"data":1,"prerenderedAt":164},["ShallowReactive",2],{"drug-alfuzosin":3},{"id":4,"schemaVersion":5,"name":6,"category":9,"class":10,"brands":13,"synonyms":17,"formulations":21,"regimens":36,"contraindications":58,"warnings":68,"renal":82,"monitoring":83,"interactions":84,"review":85,"examples":88,"atc":94,"iran":96,"usApproval":108,"links":114,"populations":130},"alfuzosin",1,{"fa":7,"en":8},"آلفوزوسین","Alfuzosin","genitourinary-sex-hormones",{"fa":11,"en":12},"آلفا-۱ بلاکر","Alpha-1 blocker",[14],{"name":15,"market":16},"Uroxatral","US",[18,19,20,7],"uroxatral","xatral","زاترال",[22],{"id":23,"form":24,"route":25,"label":26,"concentration":27,"markets":31,"refs":32},"er-10","tablet","oral","10 mg extended-release tablet (do not crush)",{"amount":28,"unit":29,"perUnit":24,"scored":30},10,"mg",false,[16],[33],{"source":34,"section":35},"fda-alfuzosin","3",[37],{"id":38,"disease":38,"label":39,"population":42,"type":46,"unit":29,"dose":47,"refs":48,"notes":51},"bph",{"fa":40,"en":41},"علائم هیپرپلازی خوش‌خیم پروستات — ۱۰ mg یک بار، پس از همان وعده غذایی هر روز","Symptoms of benign prostatic hyperplasia — 10 mg once daily after the same meal each day",{"minAge":43},{"value":44,"unit":45},18,"year","fixed",{"perDose":28,"dosesPerDay":5},[49],{"source":34,"section":50},"2",[52],{"text":53,"refs":56},{"fa":54,"en":55},"ناشتا جذب ۵۰٪ کمتر است. قرص جویده یا خرد نشود.","Absorption is 50% lower fasting. Do not chew or crush.",[57],{"source":34,"section":50},[59],{"id":60,"severity":61,"text":62,"refs":65},"ci","block",{"fa":63,"en":64},"نارسایی متوسط یا شدید کبد؛ مهارکننده‌های قوی CYP3A4 (کتوکونازول، ایتراکونازول، ریتوناویر)؛ حساسیت.","Moderate or severe hepatic impairment; potent CYP3A4 inhibitors (ketoconazole, itraconazole, ritonavir); hypersensitivity.",[66],{"source":34,"section":67},"4",[69,76],{"text":70,"refs":73},{"fa":71,"en":72},"افت فشار وضعیتی و سنکوپ؛ سرطان پروستات پیش از شروع رد شود؛ سندرم عنبیه شل حین جراحی آب مروارید (IFIS).","Postural hypotension and syncope; exclude prostate cancer first; intraoperative floppy iris syndrome (IFIS) in cataract surgery.",[74],{"source":34,"section":75},"5",{"text":77,"refs":80},{"fa":78,"en":79},"پریاپیسم؛ نارسایی کرونری؛ QT طولانی مادرزادی یا اکتسابی؛ نارسایی شدید کلیه با احتیاط.","Priapism; coronary insufficiency; congenital or acquired QT prolongation; caution in severe renal impairment.",[81],{"source":34,"section":75},[],[],[],{"status":86,"reviewer":87,"date":87},"unverified",null,[89],{"regimen":38,"formulation":23,"input":90,"expect":93},{"ageYears":91,"weightKg":92},65,75,{"perDose":28,"tabletsPerDoseRounded":5},[95],"G04CA01",{"status":97,"forms":98,"refs":103},"registered",[99],{"code":100,"en":101,"fa":102},"11904","ALFUZOSIN 10MG TAB","قرص آلفوزوسین ۱۰ میلی‌گرم",[104],{"source":105,"section":106,"url":107},"darooyab-generic","G-1515\u002FAlfuzosin","https:\u002F\u002Fwww.darooyab.ir\u002FG-1515\u002FAlfuzosin",{"kind":109,"refs":110,"id":113},"ANDA",[111],{"source":34,"section":112},"SPL approval \u002F marketing category","ANDA079013",[115,118,122,125,128],{"kind":116,"url":117,"label":113},"fda","https:\u002F\u002Fwww.accessdata.fda.gov\u002Fscripts\u002Fcder\u002Fdaf\u002Findex.cfm?event=overview.process&ApplNo=079013",{"kind":119,"url":120,"label":121},"dailymed","https:\u002F\u002Fdailymed.nlm.nih.gov\u002Fdailymed\u002FdrugInfo.cfm?setid=26fcc267-c8d7-e059-1bcf-830dded43690","FDA Alfuzosin ER",{"kind":123,"url":124,"label":8},"medlineplus","https:\u002F\u002Fmedlineplus.gov\u002Fdruginfo\u002Fmeds\u002Fa604002.html",{"kind":126,"url":127,"label":95},"who-atc","https:\u002F\u002Fatcddd.fhi.no\u002Fatc_ddd_index\u002F?code=G04CA01",{"kind":129,"url":107,"label":8},"darooyab",{"pregnancy":131,"lactation":140,"pediatric":148,"geriatric":156},{"level":132,"text":133,"quote":136,"refs":137},"caution",{"fa":134,"en":135},"برچسب خطر مشخصی برای بارداری ذکر نکرده یا داده کافی ندارد؛ فقط در صورت لزوم و با نظر پزشک.","Label states no clear risk or has limited data; use only if needed, under medical advice.","Risk Summary Alfuzosin hydrochloride extended-release tablets are not indicated for use in women.",[138],{"source":34,"section":139},"8.1",{"level":132,"text":141,"quote":144,"refs":145},{"fa":142,"en":143},"برچسب: در شیردهی با احتیاط؛ متن برچسب را ببینید.","Label: use with caution while breastfeeding; see the label text.","Risk Summary Alfuzosin hydrochloride extended-release tablets is not indicated for use in women.",[146],{"source":34,"section":147},"8.2",{"level":132,"text":149,"quote":152,"refs":153},{"fa":150,"en":151},"برچسب برای کودکان شرط، محدودیت سنی یا نکته دارد؛ جمله برچسب در زیر آمده است.","The label has conditions, age limits or notes for children; the label sentence is quoted below.","Alfuzosin hydrochloride extended-release tablets are not indicated for use in the pediatric population.",[154],{"source":34,"section":155},"8.4",{"level":132,"text":157,"quote":160,"refs":161},{"fa":158,"en":159},"برچسب: در سالمندان با احتیاط و معمولاً از دوز پایین شروع شود.","Label: use with caution in older adults, usually starting at the low end of the dose range.","Of the total number of subjects in clinical studies of alfuzosin hydrochloride, 48% were 65 years of age and over, whereas 11% were 75 and over.",[162],{"source":34,"section":163},"8.5",1792191524471]